UK Has Sought Advice On Compulsory Licensing For Vertex’ Orkambi

Pressure on Vertex over access to its cystic fibrosis drug Orkambi in England is mounting after the parliamentary undersecretary for health admitted the government has already taken advice on compulsory licensing of the product.

chess
UK Has Received Compulsory Licensing Advice On Orkambi

Vertex is under escalating pressure in the UK to give way on the pricing of its cystic fibrosis drug Orkambi (ivacaftor/lumacaftor) following a parliamentary debate on whether the government should issue a compulsory license for the drug. Steve Brine, parliamentary under secretary of state for public health and primary care, admitted that the government has already taken legal advice on whether this could be an option to provide access to treatment.

The debate came shortly after a patient-led activist group, Just Treatment, wrote to prime minister Teresa May and secretary of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography